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ABSTRACT 
 
 
  
 This project examined the methods of creating transgenic animals, the reasons for 
doing so, and the effect of this controversial new technology on society via ethical and 
legal issues.  A detailed description of what a transgenic animal is, how they are created, 
and their use in society today and in the future was followed by how transgenic animals 
have already provided much societal benefit, including information on human diseases, 
drugs to save human lives, and knowledge of the biological function of newly discovered 
proteins.  Transgenic technology should have a positive impact on society as long as 
animal suffering is kept at a minimum and used solely for the purpose of helping humans. 
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PROJECT OBJECTIVES 
 
 
 The objective of this IQP project was to examine the topic of transgenic animals 
and to discuss the effect of this controversial new technology on society.  The report 
explains to readers what transgenic animals are, how they are created, and describes the 
types of transgenic animals created to date.  The project then touches upon the ethical and 
legal issues encountered with such a breakthrough and complex technology.  Because 
transgenesis has both positive and negative impacts on animals and on society, there is 
much controversy and unclear projections on where this technology will place us in the 
future.  The goal of this paper is not to implant the idea that transgenic animals are good 
or bad, but to provide enough knowledge to allow readers to explore the topic and 
develop opinions of their own. 
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CHAPTER-1:  TRANSGENIC TECHNOLOGY 
Travis Abele 
 
Transgenesis is a relatively new technology in which the DNA of an organism is 
altered to produce a new and unnatural desired trait.  The overall genetic pool of the 
organism is kept relatively the same, but a foreign gene is inserted into an embryo prior 
to birth. The goal of this technology is to produce animals with desired benefits for 
mankind.  When done successfully, all cells and tissues of the resulting animal contain 
the foreign gene, including their germ cells (sperm or ova), so these animals will be able 
to pass this desirable gene or genes to their offspring (Wheeler, 1991).  By inserting 
certain genes into the genome of animals, thus recombining the DNA, many issues in the 
world today, most importantly health care, can be addressed.  Such animals will be able 
to model life-threatening diseases, giving researchers a better chance to develop cures, 
produce human organs for patients who need them, and produce cost-effective 
pharmaceuticals. 
 
Brief Transgenic History 
The first genetically modified organism was a bacteria created in 1973 by Stanley 
N. Cohen and Herbert Boyer that contained genetic information from a variety of 
different species (Morrow et al., 1974).  Soon after the technology was discovered, the 
Asilomar Conference was held in Pacific Grove, California to confirm that further 
research in this field should proceed under strict guidelines set by the National Institutes 
of Health in the United States, and by comparable organizations in other countries 
(Transgenic History, 2005).  
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 The first transgenic animals were mice created in 1974 by Rudolf Jaenisch, a 
professor of biology at Massachusetts Institute of Technology (Jaenisch and Mintz, 
1974).  These mice contained viral SV40 leukemia genes, and the transgenes were not 
only present in the mouse but also in its offspring (Jaenisch, 1976; Transgenic History 
2005).  Then, in 1982, Ralph Brinster of the University of Pennsylvania inserted the 
structural gene for human growth hormone into mice embryos, and noticed the mice with 
the foreign gene grew much larger than those without the gene and also passed this trait 
to its offspring (Palmiter et al., 1982; Kwiram, 1996). The transgenic mouse is shown in 
Figure-1 on the right next to a non-transgenic mouse on the left. 
 
 
 
    
 
 
 
 
 
Recombinant DNA Technology 
   Because much of the creation of transgenic animals involves the manipulation of 
DNA, an overview of exactly what DNA is, and how it is used in the development of 
transgenic animals shall be discussed in detail.  DNA, or deoxyribonucleic acid, is the 
molecule containing all the hereditary information for humans and almost every other 
Figure-1:  Picture of An Early Transgenic 
Mouse.  The transgenic mouse on the right 
contains a foreign gene for human growth 
hormone thus it grows larger (Palmiter et al., 
1982; Kwiram, 1996). 
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organism on earth. Most DNA is found in the cell nucleus, but small amounts can be 
found in the cell’s mitochondria. Every cell in the organism has essentially the exact 
same DNA. DNA contains four chemical bases: adenine (A), guanine (G), cytosine (C), 
and thymine (T). (A) pairs with (T) and (G) pairs with (C) forming bases on a helix, 
which consists of a sugar (deoxyribose) and a phosphate, as shown in Figure-2 (United 
States, 2008). The sequence of these base pairs is what makes each organism’s DNA 
unique, and is what gives each organism its unique traits. Genes are sections of the DNA 
strand that encode a defined biochemical function, usually the production of a protein. 
The sequence of the DNA bases determines the structure of a protein, and the structure of 
a protein determines its function.  Therefore, the genetic code determines what proteins 
an organism can make and their function (Seline and Friedman, 2007). These proteins 
then make the organism. 
 
 
 To change the DNA to make it recombinant, scientists combine the original DNA 
with a different strand of DNA, creating a new strand of DNA.  This recombinant DNA is 
Figure-2:  Diagram of the Structure of DNA.  DNA is a 
double helix with base pairs (horizontal rungs in the 
diagram) in a distinct sequence (What is DNA, 2008). 
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also referred to as a “chimera.” There are three different ways recombinant DNA is 
created:  Transformation, Non-Bacterial Transformation, and Phage Introduction. 
 Transformation involves inserting a piece of DNA into a vector (a plasmid DNA 
molecule acting as a carrier).  Both the plasmid vector and insert are cut with a restriction 
enzyme to create compatible ends, then the two molecules are sealed together using DNA 
Ligase. The insert contains a marker, usually an antibiotic resistance gene, which allows 
identification of cells containing recombinant molecules. The recombinant plasmid is 
then inserted into a host cell, such as E. coli specially prepared (competent) to take up 
DNA. 
 Non-Bacterial Transformation is similar to Transformation except it does not use 
bacteria as the host cell. In this process, the DNA is usually directly microinjected into 
the nucleus of the cell being transformed.  Finally, with Phage Introduction, a bacterio-
phage (virus that infects a bacterium) is used to introduce the DNA into a cell.  This 
process is similar to transformation except a virus is used to transfer the DNA to the cell. 
 Recombinant DNA is only effective when the host cell expresses the gene (makes 
RNA and protein). Thus the transgene is usually flanked by controlling DNAs that ensure 
correct expression of the transgene (Kuure-Kinsey et al., 2000). 
  
Three Most Common Ways to Create Transgenic Animals 
 Currently, the three most widely used procedures for creating transgenic animals 
are microinjection of the cloned gene(s) into the pronucleus of a fertilized egg, injection 
of recombinant embryonic stem cells into embryos, and the use of retroviruses. Some 
other less common ways are also possible, and will be discussed in later sections. 
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MICROINJECTION 
 The main purpose of the microinjection method is to expose the fertilized egg to 
the transgene before cell differentiation begins, thus allowing the gene to be prevalent in 
the organism before the organism begins to develop.  If the process works as planned, all 
cells in all tissues of the soon to be organism will contain this crucial gene.  An egg and 
sperm are fertilized in vitro, and before the two pro-nuclei fuse inside the new zygote the 
male pronucleus is microinjected with the recombinant DNA (Figure-3).  A fine point 
glass pipette (upper portion of the figure) immobilizes the embryo on one side, while on 
the other side the foreign DNA is inserted into the male pronucleus with an ultra-fine 
needle (lower portion of the figure).  As one can see in the figure, the pronucleus visibly 
swells as it is microinjected. 
 
 
 
                                                 
 
 
Figure-3:  Photograph of the Microinjection of 
DNA into the Male Pronucleus of a Single 
Celled Embryo.   An in vitro fertilized embryo is 
immobilized using a suction pipette (upper portion 
of the figure).  The male pronucleus is 
microinjected with foreign DNA using a very fine 
pulled glass needle (Wheeler et al., 1991). 
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Following microinjection, the embryo is cultured to the blastocyst stage in vitro, then 
placed back into a pseudo-pregnant female or foster mother. The embryo develops the 
same way as a typical embryo into a fetus, and normal pregnancy is observed. This 
microinjection procedure is the most efficient way today to create transgenic animal 
lines, even though only about 25% of these embryos actually produce transgenic 
offspring (Wheeler et al., 1991).  The reason for this low efficiency is unknown, but 
likely includes destruction of the embryo during microinjection, and spontaneous 
abortion of the fetus (Eide, 1997).  A visual description of the microinjection method is 
shown in Figure-4. 
 
 
 
 
 
 
 
 
 
EMBRYONIC STEM CELL INJECTION 
The second method for creating transgenic animals is somewhat similar to the 
first method discussed, but involves making embryonic stem (ES) cells transgenic instead 
of a male pronucleus.  An embyo is created by in vitro fertilization (IVF) but instead of 
being injected with foreign DNA, the embryo is cultured to the blastocyst stage. The 
Figure-4: Diagram of 
Construction of a Transgenic 
Animal by Microinjection into 
Zygote.  A transgenic mouse is 
created using the microinjection 
method.  Implantation of the 
manipulated embryo is in the 
center of the diagram  (Eide, 
1997). 
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blastocyst stage occurs about 5-7 days after fertilization. The blastocyst consists of an 
inner cell mass of embryonic stem (ES) cells and an outer trophoblast.  The word 
blastocyst means “bud” or “sac” referring to the fetus which at the time is only a cellular 
sac with a central cavity.  The ES cells are isolated then injected with foreign DNA.  
Once it has been determined that the transgene is present in the ES cells, they are injected 
into another blastocyst.  That blastocyst is then implanted into a surrogate mother as 
before to create transgenic pups (Wheeler et al., 1991).    
As with transgenic DNA microinjection, with this procedure every organ system 
of the animal usually contains transgenic DNA, including the reproductive system 
(Wheeler et al., 1991).   And the ES cells can be pre-screened to ensure transgene 
insertion prior to injection into the blastocyst, which improves efficiency.  A summary of 
the ES cell method is shown in Figure-5. This method is particularly important for 
studying the development of transgenic organisms while being able to control their genes, 
and works very well with mice. However, the DNA microinjection method works better 
on a wider variety of species. 
 
 
 
 
 
 
 
 
Figure-5:  Construction 
of a Transgenic Animal 
Using ES Cells.  ES cells 
are isolated from a 
blastocyst (upper left).  
The transgenic DNA is 
then inserted into them via 
viruses or microinjection, 
then the ES cells are 
injected back into another 
blastocyst (upper right) for 
further development  
(Eide, 1997). 
 
 12
 
VIRUSES FOR DELIVERING DNA 
 The third method for creating a transgenic animal is somewhat different from the 
first two discussed. When DNA is microinjected into the fertilized egg, DNA randomly 
inserts into the genome, and there is a possibility that the animals’ normal gene function 
will be disrupted, leading to health problems such as birth defects, brain damage, cancer, 
etc. (Gillespie, 2008). However certain viruses can be used to target where the transgenes 
are inserted. Adeno-associated viruses (AAV) have been shown to insert at specific 
locations that do not damage a host cell’s function.  However, retroviruses are more 
efficient at integrating foreign DNA, although the integration site for retroviruses is often 
random.  The biggest advantage of viral delivery is the fact that the cellular infection rate 
is very high.  
A retrovirus is a virus that contains its genetic information in RNA rather than 
DNA, and this virus can be engineered to contain a transgene. As shown in Figure-6, the 
virus is then used to infect a cell, such as an ES cell, with its RNA.  An enzyme from the 
virus (reverse transcriptase) copies the RNA to double stranded DNA. Once in the 
nucleus of the cell, the DNA sequence from the virus is inserted into the cell’s genome at 
the target spot (Gillespie, 2008). 
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Even though the retrovirus method usually leads to fewer problems with the 
organism’s development, there are concerns about new viruses being created by 
recombination with naturally occurring viruses within the animal. Also, the success rate 
for this method is very low, with only 1% of new animals possessing the transgene. 
 
Other Ways to Create Transgenic Animals 
 
NUCLEAR TRANSFER TECHNOLOGY 
Somatic cell nuclear transfer (SCNT) technology allows the construction of 
transgenic cells with the same genetic background as the host.  In nuclear transfer, a 
nucleus from a donor cell (usually a skin fibroblast cell nucleus) is removed and 
transplanted into an enucleated fertilized egg cell.  This process was used to create Dolly, 
Figure-6: Creation of a 
Transgenic Animal Using a 
Retrovirus.  In this case, an 8-cell 
embryo (purple) is infected with a 
virus containing a transgene (right), 
then the embryo is inserted into a 
foster mother as usual (center). 
The offspring of a mouse with a 
foreign gene is shown (lower). Of 
the three mice the foster mother 
gives birth to only one that is 
transgenic 
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the world’s first cloned mammal.  A modification of this process (Figure-7) uses 
unfertilized oocytes whose membranes are fused with membranes of adult transgenic 
cells.  This process was used to create the sheep Molly and Polly.  In each case, the 
embryo will gave rise to an organism containing the same background genetic 
information as the nuclear donor.  Also, these clones only share nuclear DNA, not 
mitochondrial, unlike identical twins (Strachan and Read, 1999).  Nuclear transfer 
technology is generally more efficient than microinjection. 
 
 
 
 
 
 
 
 
 
 
 
An important aspect of nuclear transfer is that the cells, cultured in vitro, once 
genetically modified, all will contain the transgene.  And depending on whether a tissue-
specific promoter was used, the transgene will be expressed in the tissue of interest. Also, 
because the cells are cultured, site-specific genetic alterations can be made by 
homologous recombination (Akagi, 2008).  Homologous recombination involves the 
Figure 7:  Diagram of the 
Somatic Cell Nuclear 
Transfer Technique.  
Shown here is the process in 
which the  transgenic sheep 
Molly and Polly were created 
by means of nuclear transfer 
technology 
(Miesfeld, 2001). 
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breaking and repair of DNA to produce a precise exchange of material between two DNA 
strands, one containing the transgene plus some host DNA, and the other being host DNA 
(Homologous Recombination, 2008).  
 A related technique, called the “Honolulu nuclear transfer technique”, is a 
technique for generating diploid egg cells, cells having a normal two similar complement 
of chromosomes. Microinjected early stage diploid oocytes are placed into calcium-free 
media containing strontium, which activates the oocytes to divide in vitro.  Cytochalasin-
B is also included in the activation medium to prevent polar body formation, which 
would cause chromosome loss (Miesfeld, 2001). This procedure is shown in Figure 8.  
 
 
 
  
Figure 8:  Diagram of the 
Honolulu SCNT Technique.  This 
parthenogenic technique creates 
diploid transgenic eggs from early 
stage diploid oocytes  (Miesfeld, 
2001). 
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 The SCNT technique, which has successfully been applied to animals but not 
humans yet, has been acclaimed as a method for treating some diseases.  For example, ES 
cells genetically identical to a patient could be created from a patient’s skin fibroblast cell 
nucleus, the ES cells could then be used to create new tissue in that same patient for 
healing a heart tissue following a heart attack.   Or in another example, skin cells could 
be reprogrammed into insulin producing cells and then placed into the pancreas of a 
diabetes patient, allowing them to produce insulin (The Future of Cloning, 1998). 
 SCNT provides faster development than microinjected animals.  For example, 
microinjection requires 44 months of development for sheep, but only 18 months for 
SCNT.  And pre-screening of the nuclei to ensure transgenesis is possible which helps 
ensure ideal protein expression (Nuclear Transfer Technology, 2005).  Figure 9 shows a 
recent history of different animal breeds genetically modified by means of SCNT.  
 
 
 
 
 
 
 
 
Figure 9:  Recent History of 
Transgenic Animal 
Production by SCNT.  Green 
denotes success, red means 
not done yet, and yellow 
means very close to being 
done successfully (Miesfeld, 
2001). 
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GENETICALLY MODIFIED SPERM 
 The final method for producing transgenic animals discussed here is less common 
than the other methods.  In the past, it has been difficult to genetically modify sperm cells 
in animals prior to fertilization because treated sperm have failed to mature under in vitro 
conditions. Noriyoshi Sakai, Ph.D, and Kayoko Kurita were able to allow immature 
sperm cells from zebrafish to survive long enough in vitro to receive foreign genes 
inserted by a retrovirus (Kurita et al., 2004). These genetically modified sperm were then 
allowed to fertilize eggs in culture, producing transgenic embryos and zebrafish.  These 
transgenic zebrafish carried the foreign gene in every cell of their bodies (not mosaic), 
including the germ cells, allowing them to produce transgenic offspring.  Scientists were 
easily able to tell whether the offspring were transgenic (Spencer, 2004). This process 
was discovered in 2004, so it is a very new technology, but there have also been reports 
of successful transgenic pigs and mice produced by sperm-mediated gene transfer. 
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Chapter-2:  Transgenic Applications 
Michelle Miller 
 
 Transgenic animals have multiple uses in modern science and medicine. 
Transgenic animals have been used as disease models for human ailments such as AIDS 
and Alzheimer’s disease. They have been modified to produce insulin in their milk 
through a process called Transpharming.  Xenotransplantation can offer hope to people 
waiting for an organ transplant by growing new organs within a different species.  They 
can even be altered to produce more food. The benefits to society that these transgenic 
animals provide as documented in this chapter will serve as a prelude to the ethical 
discussion in chapter 3.  
 
Disease Models 
 
One of the easiest ways to examine and experiment with human diseases is to use 
animal models, to allow experimentation on the animal instead of humans. Mice have 
always been a favorite model since they are small, easy to care for, have short life cycles, 
and produce large litters to provide large amounts of statistical data. The problem with 
testing diseases on mice is that the do not get most human diseases. Transgenics can 
solve this problem by inserting key genes for the disease into the genome of the entire 
animal. The animal then suffers from the same symptoms, or a part of them, that a human 
with the disease would, which in turn enables scientists to study treatments and 
medications for the disease. Scientists can also see the side effects and efficiency of the 
treatments. In terms of the FDA, if a medication satisfactorily passes the tests on animals, 
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it is then ready for human clinical trials which is the step before the drug can be released 
to the public (Transgenic Models, 2007). 
 
HIV-1 Rat 
 
 Acquired Immune Deficiency Syndrome (AIDS) is actually the later stages of 
infection from a retro-virus called Human Immunodeficiency Virus (HIV). In 2007, it 
was estimated that 33.2 million people lived with HIV on the planet. The problem with 
normal animal testing of HIV is that the virus is specific to humans; instead SIV (Simian 
Immunodeficiency Virus) was often used to test a highly related virus on primates such 
as chimpanzees. However primates are expensive and rare, whereas rats or mice are 
much more abundant and easier to study for genetic tests because of their relatively short 
life cycle and large litters (Baylor Scientists, 2001).  
HIV infected transgenic rat and mice have both been created, however the rat 
model seems to work better because of its larger size.  Rats provide more blood to collect 
and analyze and easier organ inspection. A team of scientists from University of 
Maryland’s Biotechnology Institute first created a rat with a transgenically modified 
genome that contained the mutated genome of HIV (Bunce and Hunt, 2004). The 
implanted HIV genome had the genes pol and gag spliced out to prevent transmission of 
the virus (Kohn, 2001). The original transgenic female rat which carried the spliced HIV 
genome was bred with a wild type rat; the offspring were a mix of uninfected and 
infected rats. The rats, who displayed a phenotype of cataracts, were separated based on 
the severity of their cataracts (Reid et al, 2001). A southern blot test was then performed 
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to compare wild type rats with the transgenic rat’s offspring to confirm that the offspring 
of the female transgenic rat contained the same HIV gene. The southern blot test 
indicated that the rats were indeed transgenic. By the time the rats reached the age of 5-9 
months they displayed symptoms similar to that of an AIDS patient. In addition to the 
cataracts, the rats developed kidney disease, heart problems, weight loss, and skin 
lesions.  
These rats provide a solution to the small animal experimentation problem for 
HIV/AIDS research.  The University of Maryland recently licensed the HIV-1 transgenic 
rat to Harlan Sprague Dawley, Inc., one of the world’s largest providers of rats to medical 
research facilities, which will hopefully allow for a vaccination for HIV be developed 
faster by allowing widespread availability of small animals to use for HIV research 
(University of Maryland, 2002). 
 
Alzheimer’s Mouse 
 
Alzheimer’s disease (AD) is a progressive and fatal brain disease with an 
unknown cause. It is thought however that the cause of AD could be the accumulation 
and development of senile plaques, which are abnormal clusters of  β-amyloid protein 
fragments deposited between nerve cells.  Also important are neurofibrillary tangles, 
which are twisted strands of a tau protein found within dead and dying nerve cells 
(Information, 2008). Plaques and tangles show up mostly in the cerebral cortex and 
hippocampus, the areas of the brain that control memory and cognitive thought. The 
buildups of these neurotoxic proteins associated with plaques and tangles cause a 
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dysfunction in the sending and processing of information in the brain, which in turn cause 
the symptoms of AD.  The common age for onset of symptoms for AD is 70; however 
there is an early onset AD which develops in patients 30-40’s (Alzheimer's Disease, 
2008).  
In 1995 the first transgenic mouse to show the pathology of AD was announced in 
Nature (Games, Adams et al, 1995). Professor Dave Adams from Worcester Polytechnic 
Institute and his fellow researchers used a known mutation from an early onset Indiana 
family to reproduce the symptoms of AD.  The mice developed senile plaques at about 6-
8 months, and their brains showed similar damage to the brain that you would see in an 
AD patient. However Alzheimer’s mouse did not form neurofibrillary tangles like an AD 
patient (Games, Adams et al, 1995). This same mouse model was tested by Elan 
Pharmaceuticals (California) with an antibody vaccine that removes β-amyloid, and the 
mouse showed improved cognitive function (Schenk et al., 1999).  Subsequently Elan has 
begun human clinical trials with this vaccine. 
In the past few years Frank LaFerla, a professor from the University of California, 
created transgenic mice who exhibit both plaques and tangles (Kingman, 2004). 
Previously researchers could only test medications that would get rid of the plaques on 
mice; however this new transgenic model allows them experiment with ways to get rid of 
both the plaques and tangles.  Laferla and his team of scientists tested the effectiveness of 
antibodies to the beta-amyloid protein injected into the brain in order to remove the 
plaques and tangles. Within a week of the tests the plaques and tangles had disappeared. 
The same test done with antibodies to the tau protein did not work as well (Kingman, 
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2004). The creation of the first mouse displaying AD symptoms was a huge breakthrough 
and was a catalyst for an invigorated search into the cause and possible cures for AD. 
 
Transpharmer Animals 
 
 Transgenics has also been used to make an animal produce a drug that can later be 
purified and given to the public. A transpharmer is created, like all other transgenic 
applications, by knocking out part of the animals genome and replacing it with a gene to 
produce a certain protein. Originally this was done by secreting the protein into the 
animal’s blood, however the problems that arose with that were that the proteins would 
adversely affect the animal’s physiology which restricted its uses.  But by localizing the 
production to breast tissue, there was no longer an issue of the proteins entering the blood 
stream. The proteins would secrete into the milk that the animal produced (Ziomek, 
1998). The ease of using milk for making mass-produced proteins and other chemicals is 
that there is much more freedom with the range and variety of compounds that can be 
produced since very little enters the bloodstream of the animal. In addition the drug can 
be delivered in milk form and little subsequent purification, if any, is required. The 
animals most commonly used for transphamering are sheep, cows, and goats (Houdebine 
et al., 1997).  
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Goats 
 
Human antithrombin III (hAT) is a serum glycoprotein that controls blood clots 
by inactivating the clotting factor thrombin, as well as inhibiting other clotting factors. 
This protein is very useful anticoagulant for when a person is undergoing coronary 
bypass surgery (What are the HD…2007). Genzyme Transgenics Corporation first 
created cloned transgenic goats containing the gene to produce recombinant hAT.  It was 
found that the transgenic goats did in fact produce recombinant hAT in their milk 
(Genzyme, 1999).  Subsequently, this hAT became the first FDA approved transpharmed 
medicine. 
Recently GTC Biotherapeutics has been advancing research in recombinant hAT 
produced from goats. In August of 2006, ATryn® was granted market authorization by 
the European Commission. ATryn® is GTC’s treatment for people who have Hereditary 
Antithrombin Deficiancy (HD) and are undergoing surgery where they have a high 
chance of deep vein thrombosis (ATryn®, 2008).  In the United States ATryn® has been 
granted fast track status by the FDA which is a great sign for getting it on the market 
sooner (GTC Biotherapeutics, 2008). GTC is also developing research into many other 
recombinant proteins such as albumin and alpha-1 antitrypsin (AAT) all produced from 
well-cared for transgenic herds of animals (Recombinant, 2008). 
Nexia Biotechnologies is also developing a product from transgenic goats that is 
significantly different from that of GTC. Nexia has developed a product they call 
Biosteel, which is spider silk proteins isolated from the milk of transgenic goats, which 
are then spun together (Products, Nexia).  Nexia is still determining how and to what 
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specifications to use the Biosteel for medical purposes. Biosteel also has other possible 
uses, for example spider’s silk is three times as strong as Kevlar, the material used for 
bullet-proof vests. Nexia is also researching a chemical called butyrylcholinesterase 
(BChE) which is found in small quantities in human blood. BChE has been shown to 
protect the body against nerve agents which are toxic chemicals  absorbed via skin or 
from inhalation. Nerve agents then travel through the blood stream to the nervous system 
where they proceed to wreak havoc by interrupting communications between nerves. 
Currently there are treatments for nerve agents but they must be administered quickly 
after exposure, and in most cases permanent damage still occurs. The U.S. military 
conducted studies and showed that elevated levels of BChE in the blood stream protected 
lab animals from nerve agents. The hope is that recombinant BChE, derived from 
transgenic goats milk, can be used as a protective measure for troops in a war setting 
where a nerve agent would be used, thereby reducing damage done by the nerve agent 
significantly. 
 
Sheep 
 
Alpha-1-antitrypsin Deficiency in humans generally results in problems with the 
lungs and respiratory functions. Alpha-1-antitrypsin (AAT) is a protein normally 
produced in the liver, which protects the lungs by stimulating an enzyme that fights 
bacteria and cleans the lungs of dead tissue to keep them functioning properly. AAT-
deficient patients can display a number of symptoms since AAT deficiency opens them 
up to develop many other diseases including cirrhosis, asthma, aancreatitis, gallstones, 
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emphysema, and cancer (Researchers, 2007). The current treatment for this deficiency is 
to replace the missing AAT with Prolastin, which is a medication produced by Bayer 
pharmaceuticals. Prolastin is a solution whose main active ingredient is AAT derived 
from human plasma. The problem with this medication is that human plasma is expensive 
and of short supply. In addition Prolastin has to be administered intravenously which a lot 
of patients find uncomfortable (rAAT, 2008).  
In response to the need for a better method of AAT production, PPL Therapeutics 
successfully created a transgenic sheep that produced recombinant AAT in its milk 
(Hughes, 2000). Obtaining ATT from transgenic sheep’s milk offers a much easier 
method for AAT production; in addition the ability to mass produce AAT will help lower 
the cost of the medication for AAT deficient patients.  Currently Bayer and Arriva 
Pharmaceuticals are working on getting a recombinant AAT derived from yeast, 
delivered in aerosol form, as a treatment for hereditary emphysema through FDA clinical 
trials (rAAT, 2008). 
 
Cows 
 
Human lactoferrin (hLF) is a protein that helps to protect the body from infections 
and strengthens the immune system. hLF has been found in human tears and lung 
secretions, and has been shown to fight bacteria that cause infections of the eye and lungs 
(Lactoferrin, 2008). It has also been found in large quantities in a human substance called 
colostrum, which is the milk produced by the mammary glands in the few days right 
before and after birth. Colostrum, which is also known as immune milk, helps build up 
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the newborn’s immunities, deliver essential nutrients, and helps clear the baby’s digestive 
system.  In 1989 Dutch company Gene Pharming was allowed to try to genetically 
engineer a cow which produced hLF in its milk (Krimpenfort et al, 1991). Eventually 
they produced one very famous male, Herman, who was the world’s first transgenic cow, 
and who carried the gene to produce hLF, however as it was a male it could not produce 
milk for tests. A few years later that male cow fathered a female cow that had 
recombinant hLF in her milk (Van Berkel et al, 2002). Gene Pharming then proved that 
the recombinant hLF was so similar to natural hLF that they expected it to work the 
same. In 2001 the FDA put out a “generally recognized as safe” notice for the use of 
purified hLF from bovine milk for the use in sports foods and functional foods 
(Tarantino, 2003). The ability to produce hLF in cow’s milk is very useful since milk is 
already a well established food worldwide. 
 
Xenotransplanters 
 
 One of the current major problems with getting transplants is that a patient 
waiting for an organ will oftentimes die before one becomes available. The supply of 
organs needed for transplants is so small compared to the need that a lot of people started 
to look into alternatives (Corporate, 2007). Pigs have been experimented with for quite 
some time because they have a physiology similar to humans, and are relatively cheap 
and easy to get compared to a chimpanzee (Catez, 2005). The current problem with 
xenotransplantation, the transplanting of tissue from one species to another, is that pigs 
naturally create sugars on the surface of their cells which humans recognize as foreign 
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causing immunorejection (Mooney, 1999). When the human body notices that those 
sugar shouldn’t be there, it kick starts an immune response to attack the new organ which 
is the most common reason for organ rejection. The basis behind xenotransplantation is to 
generate genetically altered animals who are missing the genes that encode the 
production of the sugar that initiates the immune response.  
Two major things hold back the transplantation of porcine organs into humans, 
immuno-rejection, and the fear of spreading diseases across the species border. Currently 
a company called Xeno Transplants Corporation is testing whether baboons have an 
immune reaction to organs transplanted from a transgenic herd of pigs they created 
(Corporate, 2007).  Their pigs are missing the gene which encodes the animal protein 
markers that cause rejection. So far their tests on rats and mice are promising (Kaiser, 
2002). In addition, their herd of pigs are also missing the Porcine Endogenous Retrovirus, 
which is one of the biggest concerns for spreading diseases between humans and pigs.  It 
is hoped that these advances in transgenics can have a huge benefit to the thousands of 
people waiting for organ transplants (Xenotransplantation, 1996).   
 
Transgenic Animals as Food Sources 
 
Transgenic animals can also be genetically modified to provide additional 
nutrients or even to grow larger. Transgenic animals are not commercially available on 
the market because of ethical and safety issues, but they are still made and used for 
research (Harper, 2006). 
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Superpig 
 
The hope behind research into pigs was to create a pig who grew faster, larger, 
and ate less food. In an attempt to do so, scientists spliced the gene for Human Growth 
Hormone (HGH) into the pigs genome. The pig, who was has been termed Superpig, 
grew larger and quicker than normal pigs, consumed less food, and had less body fat 
(Pursel 1997). However, Superpig suffered from several painful side effects of the gene 
transplant. He suffered from arthritis, gastric ulcers, stomach lesions, lack of 
coordination, and severe muscle weakness. It was then determined that the pain that was 
caused to the pig was too great to warrant further research, so scientists placed a 
voluntary moratorium on farm animal transgenesis with human growth hormone. While it 
was a good original idea, the negative side effects of human growth hormone on pigs 
makes it not viable for human consumption or the commercial market (Rexroad and 
Caird, 1994). 
 
Super Salmon 
 
While there were setbacks in the research of human growth hormone transgenesis 
on farm animals, fish, salmon in particular, were found to react well to this inserted gene. 
The reason why fish react better to human growth hormone research is that they swim in 
water so if they were to grow larger their muscles are not needed to support themselves 
against the force of gravity (Devlin et al, 2001). Transgenic salmon have been shown to 
grow 3-6 times faster than normal salmon, and can reach marketable size a year earlier 
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than other commercially produced salmon. They are also 10-30% more efficient at 
converting their food consumed into muscle weight (Fletcher and Shears, 2002).  
There are fears for the environment and the current wild salmon population if 
some of the transgenic salmon get loose (Stokstad, 2002). However transgenic salmon 
producers are taking steps to avoid those dangers (5 Myths, 2008). At the moment there 
are no transgenic animal food products on the market, but many are in development. For 
example, AquaAdvantage© Salmon from AquaBounty Farms are salmon who can grow 
from egg to market size in 1-1 ½ years, compared to traditional commercially farmed 
salmon who take 2-3 years to be marketable. AquaAdvantage© salmon and similar 
products could solve a much needed supply demand on salmon in the general market 
which would also hopefully decrease the over-fishing of wild salmon (Transgenic 
Animals, 2008). 
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Chapter-3:  Transgenic Ethics 
Michelle Miller 
 
This chapter will spotlight the arguments for and against making different types of 
transgenic animals. General arguments in favor of transgenic animals focus on the 
medical, scientific, nutritional, and financial benefits that the animals provide. On the 
other hand arguments against transgenic animals include animal welfare, environmental 
issues, and religious conflicts.  
Animals have long been genetically modified through selective breeding to be 
better at their job or to look better.  However it has not been until recent technological 
advancements that gene modification was even possible so it’s emergence as a new 
technology obviously raises questions on the basis of its experiments.  The scientific 
community has taken steps to create ethical boundaries based on failed experiments or 
mistakes.  Some general worries about transgenic animals include that containment can 
never truly be enforced, which could lead to a transgenic animal out competing its own 
species, or mating and spreading the modified genes.  Also connected to the control issue 
are worries of what genetically modified food would do to a human who ingested it. 
There is also a religious conflict in that genetically altered animals go against the natural 
order of things. In addition there are activists who argue that genetically altering animals 
affects their general welfare.  
However transgenic animals have proven to provide many benefits to humans 
including the production of drugs or simply more food, reduced need to use pesticides or 
herbicides, and a reduction in the overall number of animals used for testing. Some 
examples of things that transgenic animals have produced are outlined in the previous 
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chapter. There is also the argument that discoveries about humans should not come at the 
cost of the suffering of the animals used for the tests. The question is where does that 
balance lie, but the main trouble is that it is different for different people and for different 
types of experiments. Another trouble lies in trying to outline an ethical code for 
transgenic experiments when new discoveries in the field are happening so rapidly, which 
creates worry that scientists are doing things they will regret later. The attempt to create 
legal boundaries on transgenic research is discussed in the next chapter. 
 
Transgenic Positives 
 
The positive benefits that transgenic animals offer fall into four broad categories: 
medicinal, scientific, food enhancement and productivity, and financial.  
Medicinal uses for transgenic animals include disease models, transpharmers and 
xenotransplanters. Disease models such as the Alzheimer’s mouse and the AIDS rat have 
given scientists a way of understanding viruses and diseases in a way they couldn’t 
before. It is because of the disease models that scientists were able to use that knowledge 
to create cures and better treatments for diseases (Baylor, 2001). The use of humans for 
such experimental tests is highly unethical, therefore disease models are greatly needed. 
Transpharmers are medically beneficial because of their ability to produce 
pharmaceuticals in their mammary cells which gets secreted into their milk. Those 
pharmaceuticals can then be extracted from the milk in much larger quantities than could 
be produced using traditional methods. The production of drugs in the milk of farm 
animals has been shown to create very little side effects to the animal itself. Animals that 
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are xenotransplanters are created to have organs that are transplantable in humans. This is 
done by removing certain markers on the surface of the animal cells which usually cause 
rejection in humans. The need for transplant organs currently greatly exceeds the supply; 
the number one preventable death in the United States is waiting for an organ transplant 
(Edwards, 2006). The use of animals for organ transplants would relieve great suffering 
that many people live through while waiting for an organ. 
Scientific models are used to identify the functions of specific newly discovered 
proteins. For example by removing a certain gene that encodes for a protein that has an 
unknown function scientists can then observe the phenotype of the genetically altered 
animal to discover the function of that protein. Doing such experiments allows 
researchers to explore the gene modification as a treatment for certain disabilities. 
 Food enhancement through transgenics has been used to create animals such as 
super fish, who as explained in the previous chapter is a fish who is has been altered to 
produce extra growth hormones and therefore grow larger and faster on less food than 
other normal fish. Other animals have also been altered similarly to mature faster, grow 
more muscles, and consume less food. Animals can also be altered to be resistant to 
diseases which help with losses at farms. 
 All of the categories above also provide a financial benefit since they all relieve a 
demand on a product. While this financial benefit is not generally ethically relevant, it is 
relevant in when it comes to sponsorship of research.  All of these benefits that transgenic 
animals provide do not come without the costs of the mistakes and failures that occurred 
in their development. 
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Transgenic Negatives 
 
The negatives of transgenics usually arise from mistakes or unexpected results 
from experiments, and most of the time the animal involved ends up being deformed or 
suffers which create an ethical issue.  Disease models such as the AIDS rat or 
Alzheimer’s mouse have disease symptoms induced upon them that can lead to suffering, 
deformities, and a reduced life span (although the suffering varies widely with the disease 
being modeled, Alz mouse only gets initial symptoms of the disease while oncomouse 
can die of cancer). Animals that have increased growth hormone expression do provide 
more food and faster growth than normal animals. But as a side effect of that abnormal 
growth, the animals usually develop symptoms such as arthritis, stress, irregular heart and 
lung function, and early death. These animals have been shown to suffer greatly while 
alive.  
The main ethical issue that lies within creating transgenic animals is that by using 
them and their lifespan to solve human problems, the animals are then worth less than 
humans. This usually does not become a public ethical issue with mice, but changes if the 
animal involved is more human like such as a primate. A lot of the ethical issues 
surrounding transgenic animal creation stem from religious sections who feel that science 
is going too far, and that altering the very way an animal works is like trying to play god. 
Many people are afraid that altering an animal in such a way will have consequences that 
affect not only that animal but also the human race in general. The possibility of 
transgenic animals escaping into the wild and forever altering the ecosystem of our planet 
forever is also a huge concern. The transgenic animals could possibly wipe out their wild 
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type counterparts (Donnelley, 1993). The possibility of creating a new, dangerous 
organism that we can’t control is also a huge fear. The Beltsville Pig or Super Pig is one 
the clearest examples of negatives of transgenic research since the animal suffered so 
horribly. 
 
Alzheimer’s Mouse Ethics 
 
Alzheimer’s disease affects more than 5 million Americans, and if the sixth 
leading cause of death in the United States (“Alzheimer’s Disease”, 2008). The 
Alzheimer’s mouse that was created in part at WPI is an example of a transgenic animal 
model that provides a great benefit to the scientific and medical community that has little 
to no suffering for the animal. The mouse, which was genetically altered to form senile 
plaques, performs slower on a maze test which appears to be the extent of its suffering. 
With respect to a medical benefit, that mouse was subsequently used by Elan 
Pharmaceuticals Inc. to develop a vaccine to remove the plaques.  The vaccine was 
successful in mice (Schenk et al., 1999), but the first human clinical trial was aborted due 
to inflammation in 1% of the patients (Young, 2002), however Elan has since re-entered 
new clinical trials with a second generation vaccine that appears to cause no 
inflammation in the AD patients.  In this case of transgenesis, the medical benefits seem 
to outweigh the harm being done to the animal, if any harm is done at all. 
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Transpharmer Ethics 
 
Transpharmers are animals genetically altered to produce a desired chemical. 
Originally transpharmers were made by altering the genome of the animal to produce the 
chemical in its blood; however this had multiple negative side effects on the animal. Most 
commonly the animal just didn’t know how to react to such a large concentration of 
foreign chemicals in their blood. In response to that, scientists started making the gene 
alterations to only produce chemicals in the mammary epithelium which then get secreted 
into the animals milk, with minimal amounts actually affecting the animal’s physiology. 
So far this new method of transpharming shows very little damage done to the animal. At 
the same time these animals can produce large quantities of pharmaceuticals that require 
little if any purification. Current transpharmers are cows, goats, and sheep, and they have 
been used to create a host of useful proteins including those to help phenylketonuria 
(PKU) and cystic fibrosis, as well as insulin, growth hormone, and blood anti-clotting 
factors. There are people who feel that transpharming from animals is more ethical than 
growing them to kill and eat their meat. Even religious activists find a hard time arguing 
against transpharmers. 
 
Xenotransplanter Ethics 
 
For quite a while there has been a very serious need for organs in developed 
countries.  Animal organs are immunorejected because protein and sugar markers on the 
surface of animal cells tend to aggravate the human immune system and incite an 
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immune-rejection response. Transgenics alters the genome of the animal so that they do 
not produce the cell markers that cause rejection (Kaiser, 2002). Currently pigs are the 
best option for xenotransplantation because of their similarity to human physiology and 
their low cost compared to simians. The main concern with using xenotransplanted 
organisms is the infection and spreading of pig retro-viruses in humans. That kind of 
jumping from species to species is dangerous since it is not a virus normally residing in 
the human population. In 2000 guidelines for xenotransplantation were issued by the 
Public Health Service that requires xenotransplanters to “procure source animals from 
herds or colonies that are screened and qualified as free of specific pathogenic infectious 
agents, and that are maintained in an environment that reduces exposure to vectors of 
infectious agents (U.S. Public Health Service, 2001).” However there is still the question 
of animal welfare, and some groups argue that just keeping the animals in a non-native 
environment is enough to make the experiments unethical. The use of animals for 
transplantation requires the animal to live without an organ which can result in death or 
shortened lifespan. The ethical challenge behind xenotransplanters is whether a human 
life is worth that of an animal and vice versa. 
 
Food Sources 
 
 People are also concerned about genetically modified food reaching the general 
public when there has been little testing on the effects of genetically modified food on the 
human body. It is worried that these foods will cause some kind of harm to humans. The 
majority of the transgenic foods currently on the market are plants; however genetic 
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engineering has been used to make cows resistant to diseases such as mad cow disease. 
The thing holding back genetically altered foods from booming on the marketplace is the 
lack of consumer acceptance. A possible use for transgenic food sources includes making 
animals that are resistant to diseases to send to impoverished villages to fight global 
hunger. Transgenic food sources can also be used to bolster the nutritional value of a food 
by having it produce extra vitamins and minerals. Using transgenic plants could help 
produce more crops in less space which could save the destruction of natural 
environments of animal species. The use of transgenics on plants have significantly less 
ethical issues since it is generally accepted that plants do not have consciousnesses.  
 
Super Pig Ethics 
 
The hope behind super pig was that it was a means of producing more meat for 
less money in less time. However Super pig ended up starting a large discussion over the 
ethical boundaries of transgenic experimentation. Although Super pig’s creators surely 
had better results in minds, they did achieve their goal, the pig they had designed to grow 
faster and bigger did in fact grow bigger faster, but what they had not expected was the 
potential side effects of such an experiment. Because of his larger size, super pig 
developed arthritis, ulcers and stomach lesions, and overall muscle weakness. After the 
effects of the experiment were seen, scientists unanimously agreed on a moratorium on 
growth hormone experiments on farm animals. They did so because the discovery they 
had made was overshadowed by the intense suffering felt by the animal. Super pig is one 
of the clearest examples of a negative effect of trangenics. 
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Super Fish Ethics 
 
 The fish supply of the world are currently in danger, demand for fish as a food 
source is rising so most species are being over fished to meet the need.  Nowadays extra 
fish are bred in captivity at hatcheries, but even they are not enough so scientists decided 
to create a transgenic fish that could grow faster than normal fish and consume less food. 
The way Aqua Bounty Farms did so was by making a fish that produced growth hormone 
year round as opposed to wild type fish that only use growth hormone in spring and 
summer. Aqua Bounty Farms salmon grow to be the same size as other salmon they get 
there about six times faster. Currently they are in the process of getting their salmon FDA 
approved for testing on human consumption (Stokstad, 2002). The biggest concern about 
transgenic fish is the possibility of them escaping into the environment. Since they grow 
faster than the native species there is fear that a large scale release of transgenic fish 
could completely wipe out a species.  Companies like Aqua Bounty Farms are combating 
that issue by first sterilizing the transgenic fish so that if they were to escape they would 
not mate with a native species and would not hunt in the areas where mating occurs and 
baby salmon grow. In addition they are feeding the fish food pellets and when the fish 
escape they tend to look for items that look similar to the pellets for food such as tree 
bark. The difference between growth hormone experiments on fish versus other animals 
is that fish do not develop the same kind of negative side effects as other animals since 
they are floating in water. In fact the genetically altered salmon experience no suffering 
that we can measure. Their benefits are numerous not only to human fisheries and fish 
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markets but also to the native salmon race. These super fish could be a plausible solution 
to the demand for fish. 
 
Trangenic Ethics in Religion 
 
 Ethics are the basic principles of conduct governing an individual or group. Many 
individuals learn their moral values through religion, which in turn creates societies with 
the same or similar ethical values. Almost all of the world’s religions preach a kindness 
and respect for animals since they are God’s creatures too. Hinduism reveres the cow 
above all other animals since it is the staple of life in many countries; it is a sin to harm a 
cow. Buddhism promotes vegetarianism since animals are divine creatures who are 
greatly involved in the staple of the religion, reincarnation. When it comes to Christianity 
there are mixed messages since animals are said to be divine creations of God but that 
they have no souls and humans have dominion over them. It has been suggested that 
since humans evolved to the point to create this technology, that it might have been 
God’s will to have transgenic experimentation happen. Either way, religious values often 
are a source of friction to the advancement of transgenic sciences. 
 
Ethics and Legality 
 
 A major issue in transgenics is patenting and whether discoveries made in the 
field should be open to all. The argument for patenting is supported by the private 
business sector  since investors support research into transgenics in order to make their 
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money back when they sell the patent or a product derived from it. Without the return on 
their investments, funding for research would depress if patents were no longer issued. 
On the other hand, discoveries that could be used to help find cures and treatments for 
diseases should be available to the larger scientific community to facilitate a faster 
discovery process. In addition there is the sense of ownership that a scientists feels over 
their creations, how if those creations are living organisms can a person really own that or 
should they own intellectual property over the organism. This discussion leads to the age 
old question of what is property. Should an animal be the owner of themselves as a 
human is?  The trouble with identifying ownership when it comes to transgenic animals is 
where does the animal begin and the transplanted gene end. It is argued that the animal 
owns all that is naturally occurring, and that once they have part of them that is not 
naturally occurring is when ownership changes, however even this system has problems. 
The next chapter will go into more detail on legal arguments surrounding transgenic 
animals. 
 
Chapter Conclusions  
 
This chapter discussed the negative and positive consequences of creating 
transgenic animals, and the ethical arguments that accompany each of the uses for 
transgenic animals. Although there are many potential negative side effects to transgenic 
research, the possible benefits to many aspects of society are great. With strong 
regulation and support, transgenic animals can be used to save many human lives. The 
ethical discussions outlined in this chapter serve as a prelude to the next chapter which 
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discusses the legal issues involved in trying to solve some of the ethical disagreements 
about transgenic animals. 
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CHAPTER-4:  TRANSGENIC LEGALITIES 
Travis Abele 
 
 As mentioned in the previous chapters, the use and manipulation of transgenic 
animals has obvious advantages for humans, not just for healthcare, but also for the 
economy. But as is typical for any complex technology, laws are in effect to regulate its 
usage.  And considerable debates have taken place regarding whether animals should be 
patented.  Clearly, there can be many dilemmas for a new technology involving live 
creatures. 
 The biggest question revolving around transgenic animals is whether or not such 
animals should be patented.  In 1793 , according to Thomas Jefferson, one of the nation’s 
founding fathers, defined anything patentable as, “Any new and useful art, machine, 
manufacture, or composition of matter, and any new and useful improvement on any art, 
machine, manufacture, or composition of matter” (A Brief History…  2003).  Not only 
can animals be considered an art, machine, manufacture, or composition of matter, but in 
theory humans could be classified as a composition of matter as well, possibly making 
them patentable according to Thomas Jefferson.  The idea of patenting humans is out of 
the realm of reality, but the question of whether to patent animals is not.  
  
Patents and Transgenic Animals 
 Patents for transgenic animals are somewhat complicated.  Patents in the United 
States have history dating back to the colonial days. The earliest patents were supposedly 
passed in the 1640s by the Massachusetts Bay Colony, largely influenced by the English 
Parliament. It wasn’t until the Constitution was drafted in 1776 that patents were fully 
 48
established. Article I, section 8, clause 8 of the United States Constitution states, 
“Congress shall have power… to promote the progress of science and useful arts by 
securing for limited times to authors and inventors exclusive right to their respective 
writings and discoveries.” (A Brief History… 2003)  
 After a period of about one hundred years of revising rules for patents, such as 
whether non-U.S. citizens should be granted patents, and how long it should take, in 1870 
the legislation regarding patents was brought together in a single act.  A major 
clarification of the law was that the sale or use of the invention before the two year grace 
period of receiving the patent was illegal.  In 1952, the present structure of U.S. patent 
law was adopted. Here, the law stated that an invention had to be novel, and for the first 
time it gave a description of patent infringement. Also, the word “art” mentioned earlier 
was changed to “process” in which if an invention required multiple elements, these 
elements were defined in functional terms.  
Today, the three requirements to receive a patent are: novelty, utility, and non-
obviousness. The novelty requirement simply states that the invention must be new and 
original. The utility requirement states that the invention must be useful in some way, and 
that the invention must do what the author says it will do.  If it does not operate as it says 
it should, then the patent will be rejected.  The non-obvious requirement states that the 
invention must result in new or non-obvious characteristics in comparison to similar 
previous inventions. Factors such as color, size, and texture are obvious features, and 
changes in these will not be granted patents (Patent Requirements, 2007). 
  
 49
First Patent for Microbes, Diamond v. Chakrabarty, 1980-1983 
The first patent regarding life was granted in 1930, called the Plant Patent Act, which 
covered newly developed asexually reproducing plants.  However, until 1980, no patents 
had been allowed on animals or microbes.  During this year, the Supreme Court held the 
famous case Diamond vs. Chakrabarty, in which the Court ruled that a genetically 
modified microorganism was patentable.  Ananda M. Chakrabarty was trying to obtain a 
patent for a genetically engineered bacterium that broke down crude oil into smaller 
chains, such as gasoline, diesel, etc.  Chakrabarty wanted to obtain patents on the 
following: 
1. “The method of producing the bacterium” 
2. “An inoculum comprised of a carrier material floating on water, such as straw, 
and the  new bacteria” 
3. “The bacteria themselves” (Edwards, 2001). 
 
Initially, a patent was issued for the first two, but not for the third because according to 
The Patent Office Board of Appeals, the bacteria themselves were products of nature, and 
life itself cannot be patented.  However, The United States Court of Customs and Patent 
Appeals eventually reversed this rejection, and the patent covered not only the process 
but the organisms themselves. Apparently, the Court considered the bacterium as a 
“manufacture” and a “composition of matter” as outlined in the Patent Law of 1793.  
Shortly thereafter, the Patent and Trademark Office stated in the Official Gazette: 
“The Patent and Trademark Office now considers nonnaturally occurring non-human multicellular 
organisms, including animals, to be patentable subject matter. The Board’s decision does not 
affect the principle and practice that products found in nature will not be considered to be 
patentable subject matter. An article of manufacture or composition of matter occurring in nature 
will not be considered patentable unless given a new form, quality, properties, or combination not 
present in the original article…” 
(Edwards, 2001). 
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This final Chakrabarty ruling in 1983 stirred lots of controversy, especially in the 
business world.  McDonalds and Frito-Lay asked their suppliers not to supply them food 
from genetically modified seed, and many believed that modifying animals would 
eventually lead to the spread of disease and would be of great harm to the human race, 
causing humans to lack genetic diversity. 
 
The Harvard Oncomouse Case, 1984-1988, 1992, 1999 
 Just one year later in 1984, Harvard University scientists Dr. Philip Leger and Dr. 
Timothy Stewart inserted human oncogenes into a mouse to study the impact these 
cancer causing genes would have on the animal. The oncogenes increased the probability 
of developing neoplasms, typically malignant tumors in the mouse. The purpose of this 
experiment was to produce laboratory test animals with an increased probability of 
developing cancer (Leder and Stewart, 1984).  In 1984, these two scientists filed for a 
patent, and in 1988, the United States Patent and Trademark Office granted them U.S. 
Patent 4,736,866. 
Within the patent, it claimed the mouse as, “A transgenic non-human mammal all 
of whose germ cells and somatic cells contain a recombinant activated oncogene 
sequence introduced into said mammal, or an ancestor of said mammal, at an embryonic 
stage” (Leder, and Stewart, 1984).  This of course caused a tremendous uproar, not only 
because animals had now been patented, but many believe at the discretion of their health 
and well being. The patent also stated how these mice would be tested for 
carcinogenicity, saying “If the animals are to be used to test materials thought to be only 
weakly carcinogenic, the transgenic mice most susceptible of developing tumors are 
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selected, by exposing the mice to a low dosage of a known carcinogen and selecting those 
which first develop tumors” (Leder, 1984). The mice are clearly harmed, causing animal 
rights activists to be upset, not caring whether these cancer studies had any implications 
on humans.  
The two men also received two more patents, one in 1992, and the other in 1999.  
U.S. patent 5, 087, 571, issued in 1992, covered the method for preparing a cell culture 
from a non-human mammal, and U.S. patent 5, 925, 80 issued in 1999, covered the 
testing method using transgenic mice expressing an oncogene. 
 In Europe, Oncomouse was a different story.  The European Patent Office (EPO) 
is the organization that grants patents, and it reviewed the Harvard Oncomouse case. As 
part of the European Patent Convention, Article 53 (a) excludes patents for “the 
publication or exploitation of which would be contrary to ordre public or morality, and 
Article 53 (b) excludes patents for “animal varieties or essentially biological processes 
for the production of … animals.” (Bioethics… 2006).  In 1989, the European Patent 
Office rejected the patent, believing that the mouse was excluded as per Article 53 (b).  
However, this was appealed shortly thereafter, while the Board of Appeal claimed that 
the article only excludes “animal varieties” and considered the Harvard mouse to not be 
an animal variety, but just an animal. In 1992, the European oncomouse patent was 
granted.  
Many people did not agree with the ruling on the patent, stating that the other 
article 53 (a) about morality described the mouse. The European Patent Office had to 
weigh the benefits of the mouse, such as future impact on the lives of human being 
suffering from cancer, to the harmful effects the cancerous tumors had on the mice, and 
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whether or not these effects were important. In 2004, the European Patent Office 
officially ruled that the potential benefits of the mice experiments far outweighed the 
dangers the mice would endure, but amended the patent to only cover mice. 
 
Oncomouse in Canada 
 To this day, Canada remains the only industrialized country in the world to 
prohibit the patenting of higher life forms. The Canadian Patent Act is identical to that of 
the United States, claiming an invention to be “any new and useful art, process, machine, 
manufacture or composition of matter, or any new and useful improvement in any art, 
process, machine, manufacture or composition of matter” (Ching, 2003). Canada allows 
single-celled organisms, such as yeast and bacteria, as well as genetically modified crops 
to be patented, and animal or human cell lines.  However, the Supreme Court believes 
that more complicated forms of life, such as humans and animals, fall into a completely 
different category and should not be patented.  In 1993, Harvard obtained a patent for the 
oncogene and the process from the Canadian Intellectual Property Office, but not a patent 
for the mouse itself.  Harvard tried to appeal this decision, but in 1998 the Trial Division 
of the Federal Court dismissed the appeal. 
 Just four years later, the Canadian Federal Court of Appeal overturned the trial 
judge and allowed the mouse to be patented.  But the case was sent to Parliament, and 
with a 5-4 ruling, it was decided that a living animal cannot be patented. The Supreme 
Court concluded that the mouse is not a “manufacture” since it is a product of nature and 
not something artificially put together, nor can it be considered a “composition of 
matter”.  Justice Michael Bastarache said “Just as ‘machine’ and ‘manufacture’ do not 
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imply a living creature, the words ‘composition of matter’ are best read as not including 
higher forms” (Ching, 2003).  He also wrote, “Higher life forms are generally regarded as 
possessing qualities and characteristics that transcend the particular genetic material of 
which they are composed” (Ching, 2003).  He added, “A complex life form such as a 
mouse or a chimpanzee cannot easily be characterized as 'something made by the hands 
of man” (Kondro, 2002). 
 One of the major reasons why Canada was against the patenting of higher forms is 
because they believe that if an animal is allowed to be patentable, a living organism that 
lives and breathes similar to that of a human being, patenting of humans should be 
allowed as well. Clearly, patenting human life crosses a severe line, and they believe 
animal patents cross a similar line.  Justice Bastarche further warned in 2002 after the 
famous Oncomouse patent denial that “there is no defensible basis within the definition 
of invention itself to conclude that a chimpanzee is a ‘composition of matter’ while a 
human being is not” (Kondro, 2002). Even though this may seem to put Canada behind 
other countries in the world as far as their biotechnology industry is concerned, some 
Canadian researchers believe that this benefits them. Arnold Naimark, Director of the 
University of Manitoba's Centre for the Advancement of Medicine in Winnipeg, and 
Chair of the federal government's Canadian Biotechnology Advisory Committee, stated 
in 2002 that “the patent only gives the patent holder the right to exclude others… If there 
is no [Oncomouse] patent in Canada, there is no restriction on people being able to do 
research on the Harvard Oncomouse if they get a hold of it” (Kondro, 2002). 
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Other Patented Transgenic Animals 
Since the Harvard Oncomouse case, there have been over 600 patents awarded to 
various transgenic animals, leading to a variety of controversies. According to the law, an 
animal patent covers animals with a particular gene sequence unnatural to other animals 
within its species, and the patent allows the company to prohibit others from selling or 
using these animals without its permission for 17 years (Andrews, 1993).  The patent also 
covers whatever the animal may be producing, such as organs, pharmaceuticals, or 
antibodies.  The offspring of the transgenic animals are also covered by the patent, even 
if the chromosomes of the offspring are different than the chromosomes of the parents.  
However, the company must prove that these offspring carry the foreign gene and are 
capable of performing the special duties as outlined in the patent. 
 
TRANSGENIC FISH 
The first transgenic fish were produced in 1997 (Devlin et al., 1997),  and strict 
regulations have been imposed on transgenic fish.  Transgenic fish have been developed 
for the purposes of human nutrition, biological research, environmental monitoring, and 
aquacultural modeling.  For aquacultural purposes, fish have been genetically altered to 
improve productivity, increase their resistance to disease, and contain greater nutritional 
value (Eenennaam, 2006).  Fish tend to lay a large number of eggs, and embryonic 
development takes place mostly outside of the mother, giving them an advantage over 
other transgenic animals. However, if these fish are accidentally released into the 
environment, they are most likely to cause environmental harm than any other organism. 
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They are very difficult to contain because they are so mobile and pose the danger of 
invading native ecosystems. 
In the United States, the Food, Drug, and Cosmetics Act, as well as the FDA’s 
Center for Veterinary Medicine regulate the use of transgenic fish. To this date, no 
transgenic animals have been approved for use as food, however the Aqua Bounty 
transgenic Atlantic Salmon have been under review for five years (Eenennaam, 2006). 
These salmon are shown in Figure 1.  The Food and Drug Administration (FDA) 
evaluates the environmental risks of transgenic animals as directed by the National 
Environmental Policy Act. As far as outside the United States, there are currently no 
international standards, related to the confinement of transgenic fish and their possible 
dangerous escape into the environment. 
 
 
 
 
Figure 1:  Picture of Transgenic Salmon Containing 
a Growth-Enhancer Gene.  Such transgenic salmon 
are much larger than normal salmon (Eenennaam, 
2006). 
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DOLLY THE SHEEP 
The Roslin Institute, which originally invented cloned transgenic sheep, has been 
awarded many patents on the ground-breaking invention of nuclear transfer technology 
for transgenic animals. In December of 2007, the Roslin Institute was awarded U.S. 
Patents 7,304,204 and 7,307,198, which covered the methods of using differentiated cells 
to clone ungulate animals, fetuses, and embryos (Dolly the Sheep…2007).  These new 
patents joined a number of other patents regarding somatic cell nuclear transfer 
technology as described in chapter 1 of this report.  Roslin also possesses U.S. Patent 
7,232,938 for the cloning process that uses “fusion or microinjection of a quiescent 
ungulent donor cells” (Dolly the Sheep…2007). This process has been used over the 
years to clone numerous animals, including farm animals, rodents, cats, and dogs.  
Although the process of cloning an animal using SCNT is by itself not necessarily 
transgenic if a foreign gene is not inserted in the host genome during the process, patents 
on the sheep SCNT procedure will pertain to transgenesis in the future. 
 
Positives and Negatives for Patenting Animals 
Clearly, patenting animals gives biological scientists the motivation to pursue 
research projects related to altering the genes of animals for potential benefits to humans, 
knowing that if they are successful in developing an animal for a specific cause, there is a 
reward for them down the road.  And this reward could fund additional scientific 
advances in the future.  Any kind of new technology or invention will create numerous 
jobs within that industry, thus helping the economy. Transgenic animal technology 
appears to have very little harm on human life, as long as animals are not patented for 
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food purposes. Even if animals are created to produce more food or provide better 
nutrition to humans, they provide no dangers as long as the technology is strongly 
regulated by the FDA and the resulting food is screened numerous times for defects or 
potential hazards to the digestion by humans.  
With respect to transgenic patenting negatives, some scientists argue that 
awarding such patents actually will hinder scientific research by limiting access to the 
animals to researchers that can afford it, not to all scientists.  This argument was made 
immediately following the award of the U.S. Oncomouse patent, but as the years went on, 
and Harvard and Dupont softened their licenses, this argument has more recently taken a 
backseat.   Although the possibility of one day finding a cure for cancer using transgenic 
animals such as Oncomouse makes a strong case for allowing such animals to be created, 
especially if animal suffering is minimized using pain killers and early euthanasia, some 
scientists and politicians argue that some disease models do not portray disease in the 
same way humans would, thus the model is invalid.  Although this may be the case, the 
thousands of peer review articles that have appeared highlighting new scientific facts 
learned from transgenic animals attest to their validity for mimicking at least a portion of 
the disease.  Some scientists also believe no organs produced in an animal will work 
properly in a human, but this will only be known after we try it.   
 
Chapter 4 Bibliography 
 
“A Brief History of the Patent Law of the United States.” 2003. Ladas & Parry 
Intellectual Property Law. September 2003   
<http://www.ladas.com/Patents/USPatentHistory.html>. 
 
 58
Andrews, Edmund L. "U.S. Resumes Granting Patents on Genetically Altered Animals." 
The New York Times 03 Feb. 1993. 01 July 2008 
<http://query.nytimes.com/gst/fullpage.html?res=9F0CE3DD1139F930A35751C0A9659
58260&sec=&spon=&pagewanted=all>.  
 
Bioethics and Patent Law: The Case of the Oncomouse. 2006.  WIPO Magazine. 
<http://www.wipo.int/wipo_magazine/en/2006/03/article_0006.html>. 
 
Ching, Lim L. "Canada’s Supreme Court Rules Out Patents on Higher Life Forms." 30 
Jan. 2003.  
<http://www.mindfully.org/GE/2003/Canada-Patents-Life30jan03.htm>. 
 
Devlin RH, et al (1997) Production and Evaluation of Transgenic Salmonids.  General 
and Comparative Endocrinol. 106: 169-74. 
 
"Dolly the Sheep Creators Secure New Medical Patent." The Medical and Dental Device 
Patenting Blog. 12 Dec. 2007. 
<http://www.medicaldevicepatentattorneys.com/2007/12/articles/medical-device-
patenting-news/dolly-the-sheep-creators-secure-new-medical-patent/>. 
 
Edwards, B. 2001. “Patenting Transgenic Animals.” 
<http://mipr.umn.edu/archive/v2n1/edwards.pdf>. 
 
Eenennaam AL. 2006. “Careful Risk Assessment Needed to Evaluate Transgenic Fish.”  
<http://calag.ucop.edu/0603JAS/pdfs/BiotechFish.pdf>. 
 
Kondro (2002) "PATENTING LIFE: Canadian High Court Rejects OncoMouse." 
Science Magazine 13 Dec. 2002. 
 
Leder P and Stewart T.  1984. "Transgenic Non-Human Mammals, The Harvard 
Oncomouse.  
US Patent and Trademark Office.  Patent #4,736,866.  Cambridge, MA  
 
“Patent Requirements.” 2007. Stevens Institute of Technology. 
<http://www.stevens.edu/engineering/research/inventors_handbook/patents.html>.  
 
Perzigian, Andrew. 2003. “Genetic Engineering and Animal Rights: The Legal Terrain 
and Ethical Underpinnings.”  
<http://www.animallaw.info/articles/ddusgeneticengin.htm#IIB>.  
 
 
 
  
 59
CONCLUSIONS 
 
 
 
 This project examined several important topics with transgenic animals, including 
describing what a transgenic animal is, how one is created, different examples of 
transgenic animals, and discussing the ethical and legal issues surrounding their use.  In 
the earliest days of transgenesis, the process was extremely inefficient resulting in dead 
embryos and negative screens for the presence of the trans-gene.  But eventually the 
technology improved, and new techniques, including somatic nuclear transfer, have 
greatly improved the method with higher success rates and allowing the process to work 
on larger animals, such as cows and sheep.   
The most controversial topics associated with this technology deal with ethical 
and legal issues. Clearly, animal rights supporters are against the use of transgenic 
animals for any purpose, but the fact that these animals will have a major positive impact 
saving lives far outweighs the pain associated with some of these animals. We strongly 
support the areas of transgenesis that produce no pain in the animal, including 
transpharming and models like Alzheimer’s mouse.  For those models that can produce 
some pain to the animal, we believe such research should be continued so long as animal 
suffering is kept to a minimum, either by using pain killers when advanced disease stages 
must be studied, or by sacrificing the animal prior to advanced disease formation.  We 
also support transgenic areas such as fish food sources and xenotransplanters that involve 
animal sacrifice, because the animals do not suffer while alive, yet they clearly save 
human lives.   
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With respect to transgenic legal issues, we both agree with the U.S. Oncomouse 
court case in which animals were found to be legally patentable.  However we also 
support laws designed to minimize animal suffering, and preventing transgenic 
experiments with no clear benefit to society. We believe that if transgenic animal 
technology is allowed to be pursued more heavily, society will benefit not only medically 
but economically as well. 
 
 
